Eli Lilly (LLY): GLP-1 Dominance, AI Drug Discovery

Eli Lilly (LLYUSDT) has become the world’s most valuable pharmaceutical company, with a market capitalization near $1 trillion driven primarily by its obesity and diabetes portfolio. Mounjaro and Zepbound generated $10.1 billion combined in Q3 2025, surpassing Merck’s Keytruda to become the highest‑grossing drug franchise globally.

In January 2026, Lilly announced a $1 billion AI partnership with NVIDIA aimed at accelerating drug discovery. At the same time, its oral obesity pill orforglipron entered priority FDA review. With revenue projected to approach $94 billion by 2027, a $3.5 billion Pennsylvania manufacturing facility announced in late January, and more than $50 billion committed to U.S. manufacturing since 2020, Lilly is executing on a large‑scale expansion strategy.

The stock has returned roughly 42% over the past year, while trading in a wide range between $624 and $1,134. That volatility has created both opportunity and risk for traders.

📈 Trade Eli Lilly 24/7 on Bitget

Access LLY stock futures around the clock with up to 25x leverage. 90% off trading fees until April 30, 2026.

Trade LLY Stock Futures Now →

What Does Eli Lilly Do?

Founded in 1876 and headquartered in Indianapolis, Eli Lilly develops and manufactures prescription medicines across four core therapeutic areas. The company employs approximately 43,000 people, and its treatments reach patients in more than 120 countries.

Cardiometabolic health is the primary growth engine. Mounjaro (tirzepatide for diabetes) and Zepbound (tirzepatide for obesity) anchor the portfolio, supported by Jardiance and the legacy diabetes drug Trulicity. Orforglipron, an oral GLP‑1 pill awaiting FDA approval, and retatrutide, a next‑generation triple‑agonist injectable, represent the most important near‑term pipeline catalysts.

Oncology includes Verzenio, which generated $1.47 billion in Q3 2025, along with Jaypirca, Retevmo, Cyramza, and the recently approved Inluriyo for HR‑positive, HER2‑negative breast cancer.

Immunology spans treatments such as Taltz, Olumiant, Ebglyss, and Omvoh, addressing conditions including psoriasis, rheumatoid arthritis, and ulcerative colitis.

Neuroscience covers Kisunla for Alzheimer’s disease, Emgality for migraine prevention, and Cymbalta.

Recent News & Key Developments

Lilly entered 2026 with momentum across its pipeline, partnerships, and manufacturing footprint.

Pipeline progress continued through 2025. Four Phase 3 trials for orforglipron reported positive results. In the ACHIEVE‑3 trial, the drug demonstrated stronger blood sugar reduction than Novo Nordisk’s oral semaglutide. Retatrutide delivered up to 29% weight loss in targeted populations, with additional Phase 3 readouts expected in 2026.

Financial Health & Key Metrics

Lilly’s recent results reflect both growth and margin expansion.

Full‑year 2025 guidance was raised to $63.0–$63.5 billion in revenue and non‑GAAP EPS of $23.00–$23.70. Tirzepatide became the world’s best‑selling drug franchise in Q3 2025, with Lilly holding a majority share of new anti‑obesity and incretin prescriptions in the U.S.

Industry and Competitive Landscape

The GLP‑1 market is projected to exceed $150 billion by 2035. Eli Lilly and Novo Nordisk currently dominate, with competitors several years behind.

Lilly’s advantage in the oral market comes from orforglipron’s small‑molecule design, which avoids fasting requirements. Goldman Sachs estimates Lilly could capture roughly 60% of the oral GLP‑1 market by 2030. Retatrutide, a triple‑agonist, remains a longer‑term catalyst with potential launch around 2028.

Analyst Ratings, Volatility & Historical Performance (2025–2026)

Source: vstar

Market opinion on Lilly remains predominantly bullish, though valuation is a central debate.

Volatility context: LLY experienced significant swings in 2025 — from lows near $624 in August to highs above $1,130 in November. Key drivers include quarterly earnings beats/misses vs. elevated expectations, competitive developments from Novo Nordisk, and regulatory timelines for orforglipron.

LLY Stock Price Over the Years After Earnings

Earnings Timing: Eli Lilly typically reports Q4 and full-year results in early February. The upcoming Q4 2025 earnings call is scheduled for February 5, 2026 (Wednesday before market open). Historically, earnings have been the single largest catalyst for LLY price moves.

Growth Trend: Over the last five years, LLY has delivered a roughly 649% total return, transforming from a $150–$170 stock in early 2020 to trading above $1,000 in late 2025. This trajectory accelerated sharply starting in 2023, coinciding with the launch of Mounjaro and growing excitement around the GLP-1 market.

Earnings Reaction Patterns: In recent quarters, LLY has demonstrated high sensitivity to earnings results relative to expectations. In Q3 2025, the stock closed up over 3% on the day after beating estimates by $1.6 billion in revenue and $1.33 in EPS. However, the stock dropped sharply in earlier periods when results fell short of elevated expectations, including a decline to the $624 low in August 2025 driven in part by competitive fears and profit-taking after an extended rally.

Volatility Around Catalysts: Beyond quarterly earnings, LLY reacts significantly to FDA decisions, competitive data from Novo Nordisk, and major partnership announcements. The NVIDIA partnership announcement in January 2026 and the $3.5B Pennsylvania facility news both influenced short-term price action. For the upcoming February 5 earnings, options markets are pricing in a roughly 5–7% move in either direction.

Valuation Context: At approximately 50x forward earnings, Lilly trades at a significant premium to pharma peers (sector average ~15–20x). Bulls argue the GLP-1 growth trajectory justifies the multiple; bears point to the risk that any execution miss—on orforglipron, manufacturing, or competitive positioning—could trigger sharp corrections similar to the August 2025 drawdown.

LLY Year-by-Year Stock Price History

AI & Data Analytics Positioning

Lilly is making the largest AI investment in pharmaceutical history, positioning itself at the intersection of drug discovery and compute.

NVIDIA Co-Innovation Lab (January 2026):

The lab, announced at the J.P. Morgan Healthcare Conference, represents a first-of-its-kind collaboration in pharma. Key details include a joint investment of up to $1 billion over five years, a San Francisco Bay Area facility co-locating Lilly domain experts with NVIDIA AI engineers, infrastructure built on the NVIDIA BioNeMo platform and upcoming Vera Rubin architecture, and a "lab-in-the-loop" framework where robotic wet labs and computational dry labs operate in continuous 24/7 feedback cycles.

Beyond drug discovery, the partnership extends to clinical development, manufacturing optimization using NVIDIA Omniverse digital twins, and commercial operations.

AI Supercomputer (October 2025):

Lilly deployed the pharmaceutical industry's most powerful supercomputer—a DGX SuperPOD with 1,016 NVIDIA Blackwell Ultra GPUs delivering 9+ exaflops of AI performance. The system runs on 100% renewable electricity and will train large-scale biomedical foundation models.

Lilly TuneLab: An open innovation platform launched in 2025 that gives biotech companies access to Lilly's AI drug discovery models. Schrödinger has already integrated TuneLab into its LiveDesign drug design software, creating a two-way data flow that strengthens Lilly's models while supporting the broader ecosystem.

Strategic rationale: AI could reduce pharma R&D costs by 30–40% and shorten development timelines by 1–4 years. Lilly's approach combines automated experimentation with computational modeling, with AI agents coordinating work across digital and physical labs—including automatically generating instrument protocols and new hypotheses.

Risk Factors: Policy & Research Risks

Political risk: Both political parties have targeted drug pricing. The "Medicare cliff" in 2027 could pressure commercial pricing as insurers seek parity with negotiated government rates. However, Lilly's voluntary pricing commitments (including $50/month Medicare pricing for orforglipron) may partially offset political scrutiny.

How to Trade Eli Lilly on Bitget

Eli Lilly's growth profile and volatility (particularly around the February 5 earnings, pending orforglipron FDA decision, and ongoing competitive dynamics) create trading opportunities. Bitget Stock Futures offer key advantages:

How to Trade LLY Futures on Bitget:

1. Log into Bitget → Futures → USDT-M → Search "LLY"

2. Select leverage (consider LLY's volatility when sizing positions)

3. Choose Long (bullish) or Short (bearish)

4. Set stop-loss and take-profit levels

5. Confirm your position

Risk management: LLY can move 5–10% on earnings or major FDA news. A 10% move on 10x leverage = 100% gain or loss. Always use stop losses.

Trade LLY Stock Futures Now →

More Bitget Stock Trading Options:

● 24/7 Stock Futures Trading — Trade global stocks anytime

● 0 Gas, 0 Fee Tokenized Stocks — Cost-effective equity exposure

FAQ

Is Eli Lilly a good investment for 2026?

Lilly has strong growth fundamentals: 54% revenue growth, dominance in the $150B+ GLP-1 market, and a robust pipeline including orforglipron and retatrutide. However, the ~50x forward P/E leaves little room for disappointment. Analysts project revenue could reach $94B by 2027, but pricing pressure and competition from Novo Nordisk are real risks. Use Bitget Stock Futures for flexible position management with stop-losses.

When will Eli Lilly's oral obesity pill be approved?

Orforglipron received an FDA Commissioner's National Priority Voucher in late 2025, which expedites review. Lilly CEO David Ricks confirmed at J.P. Morgan 2026 that the company expects an FDA decision in Q2 2026. The company has already submitted the NDA and is ramping manufacturing capacity across multiple facilities in anticipation of approval. Upon approval, self-pay pricing starts at $149/month.

Can I trade Eli Lilly outside U.S. market hours?

Yes. Bitget Stock Futures enable 24/7 LLY trading. Including weekends, after-hours, and during Asian/European sessions. This is particularly valuable around the February 5, 2026 earnings release, FDA announcements, and competitive news that breaks outside regular trading hours.

Conclusion

Eli Lilly has shifted from a traditional pharmaceutical company into a growth‑driven leader shaped by GLP‑1 therapies, AI‑enabled R&D, and large‑scale manufacturing investment. While long‑term fundamentals remain strong, the stock’s premium valuation means expectations are high.

For traders, understanding both the upside drivers and downside risks is critical when approaching LLY in 2026.

Start Trading LLY on Bitget →

Disclaimer: This article is for educational purposes only and does not constitute financial advice. Stock futures trading involves significant risk of loss. Past performance does not guarantee future results. Always conduct your own research.